Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1995; 74(01): 387-390DOI: 10.1055/s-0038-1642708 Symposium Thrombi as a Target of Therapy Schattauer GmbH Stuttgart Fibrinolytic Agents: Mechanisms of Activity and Pharmacology H R Lijnen Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium , D Collen Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium › Author Affiliations Recommend Article Abstract PDF Download Buy Article PDF (293 kb) References References 1 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24 2 Matsuo O, Okada K, Fukao H, Tomioka Y, Ueshima S, Watanuki M, Sakai M. Thrombolytic properties of staphylokinase. Blood 1990; 76: 925-9 3 Lijnen HR, Collen D. Strategies for the improvement of thrombolytic agents. Thromb Haemostas 1991; 66: 88-110 4 Madison E. Probing structure-function relationships of tissue-type plasminogen activator by site-specific mutagenesis. Fibrinolysis 1994; 8 (01) 221-236 5 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-9 6 Horrevoets A JG, Smilde A, de Vries C, Pannekoek H. The specific roles of finger and kringle 2 domains of tissue-type plasminogen activator during in vitro fibrinolysis. J Biol Chem 1994; 269: 12639-44 7 Thorsen S. The mechanism of plasminogen activation and the variability of the fibrin effector during tissue-type plasminogen activator-mediated fibrinolysis. Ann NY Acad Sci 1992; 667: 52-63 8 Weisel JW, Nagaswam iC, Korshol mB, Petersen LC, Suenson E. Interactions of plasminogen with polymerizing fibrin and its derivatives, monitored with a photoaffinity cross-linker and electron microscopy. J Mol Biol 1994; 235: 1117-1135 9 Camani C, Bachmann F, Kruithof E KO. The role of plasminogen activator inhibitor type 1 in the clearance of tissue-type plasminogen activator by rat hepatoma cells. J Biol Chem 1994; 269: 5770-5 10 Andreasen PA, Sottrup-Jensen L, Kjoller L, Nykjaer A, Moestrup SK, Petersen CM, Gliemann J. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Let 1994; 338: 239-45 11 Otter M, Zockova P, Kuiper J, van Berkel TJ, Barrett-Bergshoeff MM, Rijken DC. Isolation and characterization of the mannose receptor from human liver potentially involved in the plasma clearance of tissue-type plasminogen activator. Hepatology 1992; 16: 54-9 12 Fukao H, Hagiya Y, Nonaka T, Okada K, Matsuo O. Analysis of binding protein for tissue-type plasminogen activator in human endothelial cells. Biochem Biophys Res Comm 1992; 187: 956-62 13 Muller M, Haerer W, Ellbriick D, Martin U, Konig R, Seifried E. For the GRECO Study Group. Pharmacokinetics and effects on the hemostatic system of bolus application of a novel recombinant plasminogen activator in AMI patients. Fibrinolysis 1992; 6 (02) 26 Abstract 14 Suzuki N, Suzuki S, Nagaoka N. Thrombolysis of canine femoral artery thrombus by a novel modified tissue-type plasminogen activator (E6010). Jpn J Pharmacol 1994; 65: 257-63 15 Kawai C, Hosoda S, Motomiya T, Kimata S, Yui Y, Kodama K. For the E6010 Investigators. Multicenter trial of a novel modified t-PA, E6010,by i.v. bolus injection in patients with acute myocardial infarction (AMI). Circulation 1992; 86: 1-409 (Abstract) 16 Keyt B, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J, Etcheverry T, Botstein D, Bennett WF. A faster acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91: 3670-4 17 Collen D, Stassen JM, Yasuda T, Refino CJ, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK, Bennett WF. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1 resistant glycosylation variant in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994; 72: 98-104 18 Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jain D, Wang S, Tung J, Mark GE, Shebuski RJ. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991; 84: 244-53 19 Mellott MJ, Stabilito II, Holahan MA, Cuca GC, Wang S, Li P, Barrett JS, Lynch JJ, Gardell SJ. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombolysis. Arterioscl Thromb 1992; 12: 212-21 20 Witt W, Baldus B, Bringmann P, Cashion L, Donner P, Schleuning WD. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 1992; 79: 1213-7 21 Witt W, Maass B, Baldus B, Hildebrand M, Donner P, Schleuning WD. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fastandpersistentrecanalization by intravenous bolus administration. Circulation 1994; 90: 421-6 22 de Munk G AW, Rijken DC. Fibrinolyticproperties of single-chain urokinase- type plasminogen activator (pro-urokinase). Fibrinolysis 1990; 4: 1-9 23 Lijnen HR, Stump DC, Collen D. Single chain urokinase-type plasminogen activator (pro-urokinase). . In: Cardiovascular Drug Therapy, 2nd Ed.. Messerli F. ed. W.B. Saunders Company; 1994: 166 (in press) 24 Liu J, Pannell R, Gurewich V. A transitional state of pro-urokinase that has a higher catalytic efficiency against Glu-plasminogen than urokinase. J Biol Chem 1992; 267: 15289-92 25 Liu J, Gurewich V. Fragment E-2 from fibrin substantially enhances prourokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK. Biochemistry 1992; 31: 6311-7 26 Fleury V, Lijnen HR, Angles-Cano E. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. J Biol Chem 1993; 268: 18554-9 27 Blasi F, Conese M, Moller LB, Pedersen N, Cavallaro U, Cubellis MV, Fazioli F, Hemandez-Marrero L, Limongi P, Murioz-Canoves P, Resnati M, Riittinen L, Sidenius N, Soravia E, Soria MR, Stoppelli MP, Talarico D, Teesalu T, Valcamonica S. The urokinase receptor: structure, regulation and inhibitor-mediated internalization. Fibrinolysis 1994; 8 (01) 182-8 28 Danø K, Behrendt N, Brunner N, Ellis V, Ploug M, Pyke C. The urokinase-receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994; 8 (01) 189-203 29 Lee SW, Ellis V, Dichek DA. Characterization of plasminogen activation by glycosyl-phosphatidylinositol-anchored urokinase. J Biol Chem 1994; 269: 2411-8 30 Van de Werf F, Lijnen HR, Collen D. Coronary thrombolysis with KJK2Pu, a chimeric tissue-type and urokinase-type plasminogen activator. A feasibility study in six patients with acute myocardial infarction.. Coron Art Dis 1993; 4: 929-33 31 Collen D, Lijnen HR. Staphylokinase, afibrin-specific plasminogen activator with therapeutic potential. Blood 1994; 84: 680-6 32 Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993; 87: 1850-3 33 Schlott B, Hartmann M, Giihrs KH, Birch-Hirschfeld E, Pohl HD, Vanderschueren S, Van de Werf F, Michoel A, Collen D, Behnke D. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. BioTechnology 1994; 12: 185-9
